Cloris TianMoritz Beck-Broichsitter, PhD

Associate Director, Head of Early Formulation Screening
Merck KGaA

Early Formulation Screening Service - bridging RNA and lipid capabilities towards clinical LNP development
(和訳:「脂質のスクリーニング検討を含むLNP製剤開発サービスの上市」)

発表要旨

As witnessed in recent years, RNA therapy holds great promise to revolutionize medicine and first products made their way into the market. This presentation will discuss the composition, manufacturing and analytics of lipid-based, RNA-loaded nanoparticles (LNPs) and will, furthermore, highlight our capabilities to support preclinical development requests of customers within our integrated CDMO offering.

プロフィール

After receiving his Ph.D. in Pharmaceutical Sciences in 2011, Moritz has continued his scientific career as a postdoctoral researcher with focus on the synthesis and testing of novel drug delivery systems. In 2015, he joined Bayer AG as a CMC leader and successfully transferred numerous preclinical projects into the clinics. Since 2018, Moritz is with Merck KGaA, where he first supported our innovative excipient portfolio and at present builds-up customer-facing services in the novel modality space. Moritz has authored 75+ peer-reviewed articles and patent applications in the field of drug delivery sciences.